[1]
|
Kornej, J., Börschel, C.S., Benjamin, E.J., et al. (2020) Epidemiology of Atrial Fibrillation in the 21st Century: Novel Methods and New Insights. Circulation Research, 127, 4-20. https://doi.org/10.1161/CIRCRESAHA.120.316340
|
[2]
|
Joosten, L.P.T., van Maanen, R., van den Dries, C.J., et al. (2023) Clinical Consequences of Off-Label Reduced Dosing of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation: A Systematic Review and Meta-Analysis. Open Heart, 10, e002197. https://doi.org/10.1136/openhrt-2022-002197
|
[3]
|
Suppah, M., Kamal, A., Saadoun, R., et al. (2023) An Evi-dence-Based Approach to Anticoagulation Therapy Comparing Direct Oral Anticoagulants and Vitamin K Antagonists in Patients with Atrial Fibrillation and Bioprosthetic Valves: A Systematic Review, Meta-Analysis, and Network Me-ta-Analysis. The American Journal of Cardiology, 206, 132-150. https://doi.org/10.1016/j.amjcard.2023.07.141
|
[4]
|
Memon, M.M., Siddiqui, A.A., Amin, E., et al. (2022) Novel Oral Anticoagulants versus Vitamin K Antagonists in Patients with Atrial Fibrillation after Transcatheter Aortic Valve Replacement: A Systematic Review and Meta-Analysis. Catheterization and Cardiovascular Interventions, 99, 2101-2110. https://doi.org/10.1002/ccd.30213
|
[5]
|
Sjögren, V., Grzymala-Lubanski, B., Renlund, H., et al. (2015) Safety and Efficacy of Well Managed Warfarin. A Report from the Swedish Quality Register Auricula. Thrombosis and Haemostasis, 113, 1370-1377.
https://doi.org/10.1160/TH14-10-0859
|
[6]
|
Kubitza, D., Becka, M., Wensing, G., Voith, B. and Zuehlsdorf, M. (2005) Safety, Pharmacodynamics, and Pharmacokinetics of BAY 59-7939—An Oral, Direct Factor Xa Inhibitor—After Multiple Dosing in Healthy Male Subjects. European Journal of Clinical Pharmacology, 61, 873-880.
https://link.springer.com/article/10.1007/s00228-005-0043-5
https://doi.org/10.1007/s00228-005-0043-5
|
[7]
|
Sia, J.E.V., Lai, X., Wu, X., et al. (2023) Physiologically-Based Pharmacokinetic Modeling to Predict Drug-Drug Interactions of Dabigatran Etexilate and Rivaroxaban in the Chinese Older Adults. European Journal of Pharmaceutical Sciences, 182, Article 106376. https://doi.org/10.1016/j.ejps.2023.106376
|
[8]
|
Ranzato, F., Roberti, R., Deluca, C., et al. (2023) Pilot Study on the Probability of Drug-Drug Interactions among Direct Oral Anticoagulants (DOACs) and Antiseizure Medications (ASMs): A Clinical Perspective. Neurological Sciences.
https://doi.org/10.1007/s10072-023-06992-6
|
[9]
|
Kubitza, D., Becka, M., Zuehlsdorf, M., et al. (2006) Effect of Food, an Antacid, and the H2 Antagonist Ranitidine on the Absorption of BAY 59-7939 (Rivaroxaban), an Oral, Direct Factor Xa Inhibitor, in Healthy Subjects. The Journal of Clinical Pharmacology, 46, 549-558. https://doi.org/10.1177/0091270006286904
|
[10]
|
Bai, Y., Deng, H., Shantsila, A., et al. (2017) Rivaroxaban versus Dabigatran or Warfarin in Real-World Studies of Stroke Prevention in Atrial Fibrillation: Systematic Review and Me-ta-Analysis. Stroke, 48, 970-976.
https://doi.org/10.1161/STROKEAHA.116.016275
|
[11]
|
Camm, A.J., Amarenco, P., Haas, S., et al. (2016) XANTUS: A Real-World, Prospective, Observational Study of Patients Treated with Rivaroxaban for Stroke Prevention in Atrial Fibrillation. European Heart Journal, 37, 1145-1153.
https://doi.org/10.1093/eurheartj/ehv466
|
[12]
|
The Executive Steering Committee, on behalf of the ROCKET AF Study Investigators (2010) Rivaroxaban—Once Daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K An-tagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation: Rationale and Design of the ROCKET AF Study. American Heart Journal, 159, 340-347.e1. https://doi.org/10.1016/j.ahj.2009.11.025
|
[13]
|
Eriksson, B.I., Borris, L.C., Friedman, R.J., et al. (2008) Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Hip Arthro-plasty. New England Journal of Medicine, 358, 2765-2775. https://doi.org/10.1056/NEJMoa0800374
|
[14]
|
Turpie, A.G., Lassen, M.R., Davidson, B.L., et al. (2009) Rivaroxaban versus Enoxaparin for Thromboprophylaxis after total Knee Arthroplasty (RECORD4): A Randomised Trial. The Lancet, 373, 1673-1680.
https://doi.org/10.1016/S0140-6736(09)60734-0
|
[15]
|
Ray, W.A., Chung, C.P., Stein, C.M., et al. (2021) Associa-tion of Rivaroxaban vs Apixaban with Major Ischemic or Hemorrhagic Events in Patients with Atrial Fibrillation. JAMA, 326, 2395-2404.
https://doi.org/10.1001/jama.2021.21222
|
[16]
|
Vranckx, P., Lewalter, T., Valgimigli, M., et al. (2018) Evaluation of the Safety and Efficacy of an Edoxaban-Based Antithrombotic Regimen in Patients with Atrial Fibrillation Following Successful Percutaneous Coronary Intervention (PCI) with Stent Placement: Rationale and Design of the ENTRUST-AF PCI Trial. American Heart Journal, 196, 105-112. https://doi.org/10.1016/j.ahj.2017.10.009
|
[17]
|
Kirchhof, P., Radaideh, G., Kim, Y.-H., et al. (2018) Global Prospective Safety Analysis of Rivaroxaban. Journal of the American College of Cardiology, 72, 141-153. https://doi.org/10.1016/j.jacc.2018.04.058
|
[18]
|
De Vriese, A.S., Caluwé, R., Pyfferoen, L., et al. (2020) Multicenter Randomized Controlled Trial of Vitamin K Antagonist Replacement by Rivarox-aban with or without Vitamin K2 in Hemodialysis Patients with Atrial Fibrillation: the Valkyrie Study. Journal of the American Society of Nephrology: JASN, 31, 186-196.
https://doi.org/10.1681/ASN.2019060579
|
[19]
|
Wang, L. and Yao, W. (2022) A Cohort Study on the Safety and Efficacy of Warfarin and Rivaroxaban in Anticoagulant Therapy in Patients with Atrial Fibrillation Study. BioMed Re-search International, 2022, Article ID: 4611383.
https://doi.org/10.1155/2022/4611383
|
[20]
|
Lip, G.Y.H., Frison, L., Halperin, J.L., et al. (2011) Comparative Vali-dation of a Novel Risk Score for Predicting Bleeding Risk in Anticoagulated Patients with Atrial Fibrillation: The HAS-BLED (Hypertension, Abnormal Renal/ Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) Score. Journal of the American College of Cardiology, 57, 173-180. https://doi.org/10.1016/j.jacc.2010.09.024
|
[21]
|
Rivera-Caravaca, J.M., Anguita Sanchez, M., Sanmartín Fernández, M., et al. (2023) Adverse Clinical Outcomes and Associated Predictors in Rivaroxaban-Treated Atrial Fibrillation Pa-tients with Renal Impairment. The American Journal of Cardiology, 203, 122-127. https://doi.org/10.1016/j.amjcard.2023.06.105
|
[22]
|
Escobar-Cervantes, C., Díez-Villanueva, P., Bonanad, Lozano, C., et al. (2023) Vascular Protection with Rivaroxaban in the Comprehensive Management of Atrial Fibrillation. Expert Review of Cardiovascular Therapy, 21, 791-802.
https://doi.org/10.1080/14779072.2023.2276893
|
[23]
|
Chiou, W.-R., Su, M.-I., Lee, Y.-H., et al. (2023) Re-duced-Dose Rivaroxaban Is Associated with Lower All-Cause Mortality in Older Patients with Nonvalvular Atrial Fi-brillation. Journal of Clinical Medicine, 12, Article 6686.
https://doi.org/10.3390/jcm12206686
|
[24]
|
Liu, X.-Q., Li, Z.-R., Wang, C.-Y., et al. (2023) Is a Lower Dose of Rivaroxaban Required for Asians? A Systematic Review of a Population Pharmacokinetics and Pharmacodynamics Analysis of Rivaroxaban. Pharmaceutics, 15, Article 588. https://doi.org/10.3390/pharmaceutics15020588
|
[25]
|
Shah, B.B., Shankar, A., Kumar, V., et al. (2023) Direct oral Anticoagulants vs. Vitamin K Antagonists in Patients with Antiphospholipid Syndrome: A Systematic Review and Me-ta-Analysis. Annals of Medicine and Surgery, 85, 3574-3582. https://doi.org/10.1097/MS9.0000000000000903
|
[26]
|
Alamneh, E.A., Chalmers, L. and Bereznicki, L.R. (2016) Suboptimal Use of Oral Anticoagulants in Atrial Fibrillation: Has the Introduction of Direct Oral Anticoagulants Im-proved Prescribing Practices? American Journal of Cardiovascular Drugs, 16, 183-200. https://doi.org/10.1007/s40256-016-0161-8
|
[27]
|
Riahi, N., Rozen, L. and Demulder, A. (2023) Usefullness of Heparin Calibrated Anti-Xa Activity to Assess Anticoagulant Activity of Apixaban and Rivaroxaban in Emergency Pa-tients Scheduled for Acute Interventions. Journal of Clinical Medicine, 12, Article 6785. https://doi.org/10.3390/jcm12216785
|
[28]
|
Kim, J.H., Shelat, N. and Ji, C.S. (2023) Apixaban and Rivaroxaban Anti-Xa Concentration Utilization in Clinical Practice. Journal of Cardiovascular Pharmacology, 81, 165-170. https://doi.org/10.1097/FJC.0000000000001383
|
[29]
|
Nguyen, E., White, C.M., Patel, M.R., et al. (2016) Doses of Apixaban and Rivaroxaban Prescribed in Real-World United States Cardiology Practices Compared to Registration trials. Current Medical Research and Opinion, 32, 1277- 1279. https://doi.org/10.1185/03007995.2016.1170672
|
[30]
|
Qian, J., Yan, Y.-D., Yang, S.-Y., et al. (2021) Benefits and Harms of Low-Dose Rivaroxaban in Asian Patients with Atrial Fibrillation: A Systematic Review and Meta-Analysis of Real-World Studies. Frontiers in Pharmacology, 12, Article 642907. https://doi.org/10.3389/fphar.2021.642907
|
[31]
|
Camm, A.J., Cools, F., Virdone, S., et al. (2020) Mortality in Pa-tients with Atrial Fibrillation Receiving Nonrecommended Doses of Direct Oral Anticoagulants. Journal of the American College of Cardiology, 76, 1425-1436.
https://doi.org/10.1016/j.jacc.2020.07.045
|